We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Travere

News List

EC Grants Orphan Designation to Sparsentan for IgA Nephropathy americanpharmaceuticalreview
February 24, 2021
Travere Therapeutics announced the European Commission (EC) has granted orphan designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).
Travere Announces Orphan Drug Designation for IgA Nephropathy Treatment americanpharmaceuticalreview
January 20, 2021
Travere Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).